PALISADE-4 did not meet primary or secondary endpoints in the overall population, but post-hoc analyses showed significant benefit for fasedienol in patients with very severe social anxiety disorder. Safety remained favorable, and plans are underway to pursue an LSAS-based registrational pathway wi…
PALISADE-4 did not meet primary or secondary endpoints in the overall population, but post-hoc analyses showed significant benefit for fasedienol in patients with very severe social anxiety disorder. Safety remained favorable, and plans are underway to pursue an LSAS-based registrational pathway with the FDA.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
